… Currently, clopidogrel is recommended for treatment of patients with acute coronary …
inhibition responders with clopidogrel as well as non-compliance to dual antiplatelet treatment are …

… newer P2Y12 inhibitors; P … P2Y12 inhibitor was associated with treatment-by-subgroup
interactions for clinical presentation (acute versus chronic coronary syndrome) and type of P2Y12 …

… Introduction: Inhibition of P2Y 12 platelet receptors consists a crucial target of pharmacologic
treatment in acute coronary syndrome patients. Several controversial issues however still …

… This study sought to evaluate the impact of treatment with prasugrel and high-dose clopidogrel
on the basis of platelet function testing in patients with acute coronary syndrome (ACS) …

… discharged with diagnosis of Acute Coronary Syndrome) registries were … At Cox multivariable
analysis, potent P2Y12 inhibitors … Potent P2Y12 inhibitors did not increase the risk of MB in …

… and P2Y 12 inhibitors remain commonly prescribed antiplatelet drugs in the treatment of …
Despite established benefits of dual antiplatelet therapy (DAPT) in the setting of acute coronary …

… Laboratory and clinical data have convincingly shown the benefit of P2Y 12 inhibition
combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous …

… treatment-specific covariates such as choice of access site, P2Y12 inhibitor use, dose and
timing of P2Y12 inhibitor … the relationship of novel P2Y12 inhibitor use and access site on the …

… Proton-pump inhibitors (PPIs) are commonly prescribed in acute coronary syndrome (ACS)
patients … We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and …

… or silent) or Global registry of Acute Coronary Events (GrACE) score> 140 and undergoing
a rapid invasive strategy. Despite providing better inhibition of platelet function at the time of …